| The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms JD Khoury, E Solary, O Abla, Y Akkari, R Alaggio, JF Apperley, R Bejar, ... leukemia 36 (7), 1703-1719, 2022 | 2858 | 2022 |
| The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms R Alaggio, C Amador, I Anagnostopoulos, AD Attygalle, IBO Araujo, ... Leukemia 36 (7), 1720-1748, 2022 | 2618 | 2022 |
| Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia JC Byrd, JR Brown, S O'Brien, JC Barrientos, NE Kay, NM Reddy, ... New England Journal of Medicine 371 (3), 213-223, 2014 | 2020 | 2014 |
| Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia JA Burger, A Tedeschi, PM Barr, T Robak, C Owen, P Ghia, O Bairey, ... New England Journal of Medicine 373 (25), 2425-2437, 2015 | 1845 | 2015 |
| Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia JC Byrd, B Harrington, S O’Brien, JA Jones, A Schuh, S Devereux, ... New England Journal of Medicine 374 (4), 323-332, 2016 | 1082 | 2016 |
| Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia N Goardon, E Marchi, A Atzberger, L Quek, A Schuh, S Soneji, P Woll, ... Cancer cell 19 (1), 138-152, 2011 | 767 | 2011 |
| Factors influencing success of clinical genome sequencing across a broad spectrum of disorders JC Taylor, HC Martin, S Lise, J Broxholme, JB Cazier, A Rimmer, ... Nature genetics 47 (7), 717-726, 2015 | 446 | 2015 |
| Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label … P Hillmen, T Robak, A Janssens, KG Babu, J Kloczko, S Grosicki, ... The Lancet 385 (9980), 1873-1883, 2015 | 428 | 2015 |
| Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns A Schuh, J Becq, S Humphray, A Alexa, A Burns, R Clifford, SM Feller, ... Blood, The Journal of the American Society of Hematology 120 (20), 4191-4196, 2012 | 387 | 2012 |
| Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial S Stilgenbauer, B Eichhorst, J Schetelig, P Hillmen, JF Seymour, S Coutre, ... Journal of Clinical Oncology 36 (19), 1973-1980, 2018 | 364 | 2018 |
| Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: the CLARITY study P Hillmen, AC Rawstron, K Brock, S Muñoz-Vicente, FJ Yates, R Bishop, ... Journal of clinical oncology 37 (30), 2722-2729, 2019 | 289 | 2019 |
| Molecular high-grade B-cell lymphoma: defining a poor-risk group that requires different approaches to therapy C Sha, S Barrans, F Cucco, MA Bentley, MA Care, T Cummin, H Kennedy, ... Journal of Clinical Oncology 37 (3), 202-212, 2019 | 278 | 2019 |
| SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage R Clifford, T Louis, P Robbe, S Ackroyd, A Burns, AT Timbs, ... Blood, The Journal of the American Society of Hematology 123 (7), 1021-1031, 2014 | 264 | 2014 |
| The complete costs of genome sequencing: a microcosting study in cancer and rare diseases from a single center in the United Kingdom K Schwarze, J Buchanan, JM Fermont, H Dreau, MW Tilley, JM Taylor, ... Genetics in Medicine 22 (1), 85-94, 2020 | 263 | 2020 |
| Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of … AR Pettitt, R Jackson, S Carruthers, J Dodd, S Dodd, M Oates, ... Journal of Clinical Oncology 30 (14), 1647-1655, 2012 | 246 | 2012 |
| Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations A Pellagatti, RN Armstrong, V Steeples, E Sharma, E Repapi, S Singh, ... Blood, The Journal of the American Society of Hematology 132 (12), 1225-1240, 2018 | 220 | 2018 |
| Diagnostic power of laboratory tests for hereditary spherocytosis: a comparison study in 150 patients grouped according to molecular and clinical characteristics P Bianchi, E Fermo, C Vercellati, AP Marcello, L Porretti, A Cortelezzi, ... haematologica 97 (4), 516, 2012 | 218 | 2012 |
| Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib FT Awan, A Schuh, JR Brown, RR Furman, JM Pagel, P Hillmen, ... Blood advances 3 (9), 1553-1562, 2019 | 216 | 2019 |
| Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. D Oscier, C Dearden, E Erem, C Fegan, G Follows, P Hillmen, T Illidge, ... British journal of haematology 159 (5), 2012 | 205 | 2012 |
| Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results JC Byrd, WG Wierda, A Schuh, S Devereux, JM Chaves, JR Brown, ... Blood, The Journal of the American Society of Hematology 135 (15), 1204-1213, 2020 | 195 | 2020 |
